BetterLife Pharma Inc.
BETR
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -82.50% | 23.81% | 31.47% | 68.93% | 82.73% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -76.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 283.64% | -34.06% | -41.12% | -97.58% | -115.17% |
| Change in Net Operating Assets | -104.43% | -50.95% | -23.54% | -90.90% | -67.29% |
| Cash from Operations | 5.07% | 4.47% | 20.26% | -58.89% | 32.46% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -69.26% | -56.37% | -69.45% | 137.05% | 169.66% |
| Repurchase of Common Stock | -- | -- | 59.95% | 59.95% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -51.21% | -96.71% | -- | -100.00% |
| Cash from Financing | -9.75% | -3.27% | -20.53% | 81.24% | 88.53% |
| Foreign Exchange rate Adjustments | -103.85% | -100.00% | -100.00% | -100.00% | 123.42% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -247.46% | 53.07% | -26.51% | 114.79% | 102.14% |
